

Botanic Healthcare invests over Rs 25 Cr in liposomal manufacturing facility in Hyderabad

10 September 2025 | News

The unit incorporates Botanic Healthcare's patent-filed DFS™ (Dietary Fiber Stabilised) Technology



Botanic Healthcare, a global leader in natural ingredients and nutraceutical innovation, has launched its dedicated Liposomal Manufacturing Facility in Hyderabad with an investment of over Rs 25 crore.

This expansion marks a significant milestone in advancing delivery technologies designed to enhance bioavailability and effectiveness across various health and wellness categories.

With a raw material capacity of over 8,500 metric tonnes annually, the LipsoBio® facility will produce powdered liposomal vitamins and minerals, botanically enriched beadlets, and customized formulations.

The unit incorporates Botanic Healthcare's patent-filed DFS™ (Dietary Fiber Stabilised) Technology, which enables superior stability and consistent performance in liposomal formats.

This combination of cutting-edge technology and strict quality protocols ensures the company's liposomal products meet international regulatory standards and deliver consistent performance for nutraceutical, pharmaceutical, cosmeceutical, and functional food applications.

The new unit has already created over 50 high-value jobs across R&D, manufacturing, and quality operations, while also

generating indirect opportunities for local suppliers and vendors.

Leading companies worldwide are incorporating Botanic Healthcare's LipsoBio® liposomal ingredients into their formulations and successfully launching products that are generating strong market returns. Our innovative portfolio including, LipoGlo™ (Liposomal Glutathione), LipoQ10™ (Liposomal CoQ10), and Lipomac™ (Liposomal Vitamin C) is creating measurable impact across markets. A leading Korean company has recently launched LipsoBio®.

Strategically designed to serve both domestic and international markets, LipsoBio® strengthens Botanic Healthcare's supply network across South Korea, Taiwan, North America, Europe, and Asia-Pacific.

With integrated R&D and pilot-scale facilities, the new unit also accelerates product development, enabling the company to bring innovative formulations to market more quickly and efficiently.